Advancing ATMP innovation in West Sweden

Lots to check out when you are in Gothenburg for ISCT Europe Sept 4-6

This year’s ISCT Europe regional meeting is being held in Gothenburg, in the west of Sweden. When you are in town you might want to get around and visit some of the world class ATMP initiatives going on in the region, including the recently opened CCRM Nordic Hub. Below is a quick overview of some ongoing  and recent ATMP activities in West Sweden, centering around Gothenburg.

West Sweden is rapidly advancing in the ATMP field, not least through AstraZeneca’s R&D site in Mölndal with a strong focus on regenerative medicines and ATMPs. GoCo Health Innovation City is emerging as a key innovation hub, attracting leaders like CCRM Nordic, a new national centre addressing bottlenecks in ATMP production and commercialization. Companies such as Cellink, Fluicell, Elicera Therapeutics, Takara Bio and VERIGRAFT are developing groundbreaking ATMPs, often in collaboration with Sahlgrenska Academy and Sahlgrenska University Hospital, which is already treating various diseases with advanced therapies.

Here are just a few of the recent ATMP developments in West Sweden:

• Drottning Silvia’s Children’s Hospital in Gothenburg has launched the Nordic region’s first ATMP center dedicated to children. Read more (in Swedish).
• West Sweden has taken a leading role in PRECISEU – a prestigious, 22.7 million euros European initiative to accelerate implementation of precision medicine. Learn more.
• Sahlgrenska Science Park – in collaboration with Region Västra Götaland, the ATMP Center and Gothia Forum at Sahlgrenska University Hospital, and CCRM Nordic – was awarded a European Social Fund grant for the “Competence development for ATMP” project, which aims to enhance skills across diverse healthcare professional groups in response to advancements in ATMPs. Learn more.
• New Modality Support (NMS) — a collaboration between Sahlgrenska Academy, Sahlgrenska University Hospital and GU Ventures, was established with the mission to support the commercial development of research projects within the national drug development initiatives OligoNova and CCRM Nordic. Learn more.
• VERIGRAFT shared a positive progress update from an ongoing Phase I/II clinical trial in which patients are being treated with our Personalized Tissue-Engineered Vein (P-TEV) product. Learn more.
• A Sahlgrenska Academy research team received an SEK 10 million grant from Cancerfonden to take cell therapy to a new level. Learn more.

To learn more about ATMP partnerships with this part of the country, get in touch with the Sahlgrenska ATMP-centre!

Hospital ATMP centers (atmpsweden.se)

Image: iStock / Natali_Mis